BKBanu Betul Kocaman

Banu Betul Kocaman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Banu Betul Kocaman has a total of 109 co-authors. Here are the top co-authors by number of shared publications:

  • Ilkin Muradov

    Division of Endocrinology and Metabolism, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Türkiye

    9 shared publications
  • Lala Soltanova

    Division of Endocrinology and Metabolic Diseases, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Türkiye

    8 shared publications
  • Pinar Kadioglu

    Division of Endocrinology and Metabolic Diseases, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Türkiye

    7 shared publications
  • Serdar Sahin

    Division of Endocrinology and Metabolism, Department of Internal Medicine, İstanbul University-Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye

    6 shared publications
  • Emre Durcan

    Division of Endocrinology and Metabolic Diseases, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey

    5 shared publications
  • Serhat Uysal

    Department of Endocrinology and Metabolism, Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty, Istanbul, Turkey

    5 shared publications

Latest Publications

  • Long-Term Outcomes and Predictors of Recurrent Weight Gain After Sleeve Gastrectomy, Roux-En-Y Gastric Bypass, and One Anastomosis Gastric Bypass: Turkish Metabolic and Bariatric Surgery Follow-up Study (TMBS Study)

    by Sinem Kiyici, Nizameddin Koca, Zehra Yagmur Sahin Alak, Pinar Uzgec Guller, Deniz Sigirli, Özgen Çeler, Hamiyet Yılmaz Yaşar, Arzu Or Koca, Hakan Buluş, Semin Melahat Fenkci, et al.

  • Open Access

    Thyroid-Stimulating Hormone Suppression Therapy and Its Association with Anxiety, Depression, Hypomania, and Quality of Life in Differentiated Thyroid Cancer

    by Aysel Selimzade, Banu Betul Kocaman, İlKin Muradov, Lala Soltanova, Serdar Şahin, Burç Çağrı Poyraz, Mustafa Sait Gönen

    Objective: This study aimed to investigate the impact of thyroid-stimulating hormone (TSH) suppression therapy on psychological outcomes and quality of life in patients with differentiated thyroid carcinoma (DTC), with particular focus on anxiety, depression, hypomania, and related hormonal parameters. Methods: A total of 87 adult patients with DTC receiving levothyroxine therapy were evaluated. Participants were grouped according to their TSH levels: <0.1, 0.1-0.5, and 0.6-4.2 mIU/L. Psychometric evaluations included the Beck Anxiety Inventory, Beck Depression Inventory, Hypomania Checklist-32, and Quality of Life Short Form (SF-36) Quality of Life Scale. Thyroid function tests and clinical parameters were recorded. Comparative, correlational, and multivariable regression analyses were performed. Results: No significant differences were found in psychometric scores or SF-36 subdomains among the TSH-based groups. However, a weak positive correlation was identified between TSH levels and anxiety scores (r = 0.175, P = .044), while T3 levels were inversely correlated with depression scores (r = −0.216, P = .045). These exploratory associations did not remain statistically significant in multivariable linear and logistic regression analyses. No independent associations were identified between TSH categories or thyroid hormone levels and psychological outcomes. Conclusion: The TSH suppression therapy does not appear to significantly affect quality of life or mood-related symptoms in a categorical manner. Although these associations were attenuated in regression analyses, subtle relationships among TSH, T3, and psychological parameters may still exist, suggesting that psychological outcomes are influenced by multiple clinical and psychosocial factors. These findings support the need for individualized treatment strategies that consider both oncologic control and patient well-being. Cite this article as: Selimzade A, Kocaman BB, Muradov I, et al. TSH suppression therapy and its association with anxiety, depression, hypomania, and quality of life in differentiated thyroid cancer. Endocrinol Res Pract. Published online August 1, 2026. doi: 10.5152/erp.2026.26918.

  • Cross-sectional comparison of cardiometabolic markers in transgender men receiving gender-affirming hormone therapy

    by Ilkin Muradov, Serhat Uysal, Banu Betul Kocaman, Lala Soltanova, Ogulcan Karali, Oguzhan Karali, Enes Karaca, Senol Turan, Pinar Kadioglu, Emre Durcan

    Objective Cardiovascular diseases (CVD) are the most common cause of death in the world. A number of scoring systems have been proposed to predict CVD risk. In this study, we aimed to assess the cardiovascular risk scores of transgender men receiving gender-affirming hormone therapy (GAHT). Methods A total of 73 participants were included in this cross-sectional study: 43 transgender men, 15 cisgender men, and 15 cisgender women. For each participant, sociodemographic data were collected, glucose, lipid profiles and total testosterone levels were measured and the atherogenic index of plasma (AIP) and visceral adiposity index (VAI) were calculated. Results The mean age of transgender men was 29.1 ±5.7. The neck circumference (NC), waist-to-hip ratio (WHR) and Waist-to-Height Ratio (WtHR) of transgender men was statistically higher than that of cis-women (p < 0.001, for all). Also, AIP was significantly higher in transgender men compared to cis- women (p = 0.003). Conclusion In conclusion, transgender men receiving GAHT exhibited differences in several cardiometabolic and anthropometric markers compared with cisgender women, with a profile more closely resembling that of cisgender men. These findings should be interpreted as descriptive differences rather than evidence of increased cardiovascular risk, particularly in the context of a cross-sectional design. The observed reduction in HDL cholesterol may be of clinical interest. Further longitudinal studies are warranted to better elucidate the long-term cardiometabolic effects of GAHT.


  • Open Access

    Does persistent hyperprolactinemia contribute to bone loss independently of estrogen deficiency in postmenopausal women?

    by Ali Tunc, Ilkin Muradov, Mehmet Umut Capar, Banu Betul Kocaman, Mayis Farajli, Sebnem Yogurtcu, Oguz Alp Baykal, Sabriye Sibel Taze, Emre Durcan, Serdar Sahin, et al.

    Objective: To evaluate bone mineral density (BMD) in postmenopausal women with prolactinoma diagnosed during the premenopausal period and to compare skeletal outcomes according to prolactin status during drug-free follow-up. Methods: This retrospective cross-sectional single-center study included 42 postmenopausal women with prolactinoma. Patients were classified as hyperprolactinemic or normoprolactinemic based on serum prolactin levels at the last follow-up visit. BMD was assessed by dual-energy X-ray absorptiometry at the lumbar spine and femoral neck. Clinical variables were compared between groups. Correlation analysis, receiver operating characteristic (ROC) analysis, and multivariable logistic regression were performed. Results: Lumbar spine BMD was significantly lower in hyperprolactinemic patients than in normoprolactinemic patients (0.861 ± 0.124 vs. 0.960 ± 0.129 g/cm², p = 0.022), whereas femoral neck BMD did not differ. Patients with hyperprolactinemia had longer cumulative exposure to hyperprolactinemia and required longer and higher-dose cabergoline treatment. Baseline prolactin levels were higher in patients with osteoporosis and showed potential discriminatory value for identifying osteoporosis (AUC = 0.861). Lumbar spine BMD and T-scores were inversely correlated with prolactin levels. In multivariable analysis, baseline prolactin level remained independently associated with low BMD. Conclusion: Persistent hyperprolactinemia is associated with lower lumbar spine BMD in postmenopausal women with prolactinoma. Baseline prolactin level and cumulative exposure to prolactin excess appear to be important contributors to skeletal deterioration, supporting the need for routine bone health assessment during long-term follow-up.

  • Open Access

    Effects of Time-Restricted Eating on Circadian Cortisol Secretion and Obesity-Related Metabolic Markers in Cushing’s Disease: A Pilot Study

    by Lala Soltanova, Ceren Iseri, Serdar Sahin, Mihriban Kara, Suzan Aydin Guclu, Busra Yesilova, Ilkin Muradov, Banu Betul Kocaman, Pinar Kadioglu

    Purpose: The aims of this study were to evaluate the feasibility of time-restricted eating (TRE) in patients with Cushing’s disease (CD) and assess its effects on body weight and metabolic parameters. Methods: Twelve CD patients in remission with obesity were enrolled in a TRE program restricting food intake to 10:00–18:00. Anthropometric data, glycemic and lipid profiles, and circadian cortisol secretion were assessed at baseline and post-intervention. Serum cortisol levels were measured at multiple time points to evaluate diurnal patterns. Results: Nine patients completed the study. Over the 12-week period, participants showed a significant reduction in body weight, with median values decreasing from 93.8 kg [83.1–106.5] to 82.6 kg [76.9–100.3] (p = 0.011). Body mass index (BMI) also declined from 37.6 kg/m2 [34.2–39.7] to 34.4 kg/m2 [32.6–38.3] (p = 0.012). No statistically significant changes were observed in fasting glucose, HbA1c, or lipid parameters. Notably, 24 h urinary free cortisol levels significantly decreased (p = 0.01), and serum cortisol showed a downward trend at all measured time points, with the most pronounced reductions during mid-day and evening hours. No clinical or biochemical evidence of CD relapse was observed during the 12-month follow-up. Conclusions: Time-restricted eating is a feasible and well-tolerated dietary approach for patients with CD in remission, promoting weight loss and modest improvements in metabolic markers and cortisol rhythmicity.


  • Open Access

    The silent burden: Alexithymia and quality of life in acromegaly patients

    by Lala Soltanova, Ahmet Bera Aygun, Banu Betul Kocaman, Ilkin Muradov, Sabriye Sibel Taze, Senol Turan, Pinar Kadioglu, Emre Durcan

    Background: We aim to investigate the potential link between the physical changes associated with acromegaly and the development of alexithymia, as well as its related psychopathological outcomes and impact on quality of life. Methods: The study included 137 patient with acromegaly and 125 control group patients. Body Image Scale (BIS), Toronto Alexithymia Score-20 (TAS-20), Hospital Anxiety and Depression inventory (HAD), Short Form-36 (SF-36) and Acromegaly Quality of Life Scale (AcroQol) were used to the patients. Results: In the acromegaly group, TAS-20 total scores, as well as the Difficulty Identifying Feelings (DIF) and Difficulty Describing Feelings (DDF) subscale scores, were higher compared to the control group (51 vs. 44, p < 0.01; 16 vs. 12, p < 0.01; and 12 vs. 11, p < 0.01, respectively). In contrast, no notable difference was observed in the Externally Oriented Thinking (EOT) scores between the groups. The prevalence of alexithymia was markedly higher in individuals with acromegaly (16.7%) than in the control group (3.2%, p < 0.001). A positive correlation was found between alexithymia and both depression and anxiety scores ( r = 0.469, p < 0.001; r = 0.377, p < 0.01, respectively). In contrast, alexithymia was negatively correlated with SF-36, AcroQoL and BIS ( r = − 0.426, p < 0.01; r = − 0.465, p < 0.01; r = − 0.364, p < 0.01, respectively). Patients with acromegaly reported poorer body image and a higher rate of impaired body perception compared to control group (43.7% vs. 19.2%, p < 0.01). Conclusion: The present study demonstrates that alexithymia is more prevalent in patients with acromegaly compared to controls and often persists even after remission.

  • Crooke Cell Adenoma: Is Its Aggressiveness Overestimated? Evidence From a Single‐Centre Experience

    by Ilkin Muradov, Serdar Sahin, Sumeyye Akpinar, Ali Tunc, Banu Betul Kocaman, Lala Soltanova, Cansu Turker Saricoban, Nil Comunoglu, Necmettin Tanriover, Nurperi Gazioglu, et al.

    Objective: Crooke cell adenomas (CCAs) are considered rare and potentially aggressive variants of corticotroph adenomas. However, data on their clinical behaviour remain limited. This study aimed to compare the clinical, biochemical, radiological, and surgical outcomes of patients with CCAs and non‐CCA Cushing's disease (CD). Material and Methods: We retrospectively analyzed patients diagnosed with CD at our tertiary Pituitary Centre. Clinical presentation, baseline biochemical characteristics, tumour size, Ki‐67 index, remission rates, recurrence, and presence of residual tumour on follow‐up MRI were compared between CCA and non‐CCA groups. Results: At baseline, patients with CCAs ( n = 21) and non‐CCAs ( n = 60) demonstrated comparable biochemical profiles, except for ACTH levels, which were higher in the CCA group compared with the non‐CCA group ( p = 0.007). Remission and recurrence rates at 3, 6, and 12 months did not differ significantly between the two groups ( p > 0.05 for all). However, CCAs tended to present with larger tumour sizes and higher Ki‐67 proliferation indices than non‐CCAs ( p = 0.055 and p = 0.05, respectively). Moreover, residual pituitary lesions were more frequently detected on follow‐up MRI among patients with CCA ( p = 0.005). Conclusion: Our findings suggest that CCAs may not be as aggressive as previously assumed with respect to biochemical remission and recurrence rates. Nonetheless, their larger tumour size, higher proliferative index, and increased likelihood of residual disease underscore the importance of careful long‐term follow‐up. Further multicenter studies are warranted to better characterize the clinical course of CCAs.


  • Open Access

    Association of serum androgen levels with Framingham Cardiovascular Risk Score in individuals with obesity

    by Banu Betul Kocaman, Feray Akbas

    Obesity is strongly associated with increased cardiovascular morbidity and mortality. Although traditional risk factors are incorporated into widely used c

  • Psychological profiles of patients with acromegaly: personality traits, quality of life, and clinical correlates

    by Banu Betul Kocaman, Yusuf Cicek, Serdar Sahin, Ahmet Burhan Dogan, Serhat Uysal, Ilkin Muradov, Lala Soltanova, Sabriye Sibel Taze, Nazife Gamze Usta Saglam, Emre Durcan, et al.

    Objective This study evaluated temperament, character dimensions, anxiety, depression, and quality of life (qol) in patients with acromegaly, and examined their associations with clinical variables including disease activity, duration, treatment modality, and tumor characteristics. Methods In a cross-sectional study, 77 patients with acromegaly and 99 healthy controls with no difference in age and sex compared to patients completed the Temperament and Character Inventory–Revised (TCI-R), Hospital Anxiety and Depression Scale (HADS), and Acromegaly Quality of Life Questionnaire (AcroQoL). Patients were subgrouped by remission status, treatment type, and histopathological findings. Between-group comparisons and correlation analyses were performed. Results Compared with controls, patients with acromegaly exhibited higher impulsiveness but lower levels of emotional warmth, persistence, and self-directedness. Higher self-acceptance scores were associated with remission, while female patients exhibited significantly lower AcroQoL-Physical scores than male patients. IGF-1 levels positively correlated with novelty seeking. Qol was negatively correlated with harm avoidance, anxiety, and depression, whereas both anxiety and depression were positively associated with harm avoidance. Conclusions Acromegaly is associated with distinct personality patterns that may influence coping, well-being, and treatment experiences. These findings underscore the potential value of integrating psychosocial assessment and personalized support into the management of acromegaly, and highlight the need for further studies to clarify underlying neurobiological and cultural influences.


  • Open Access

    A Simple Reminder that Increases Levels of Physical Activity and Improves Glycemic Control in Patients with Type 2 Diabetes

    by Lala Soltanova, Burcu Saglamer, Emre Durcan, Serhat Uysal, Ilkin Muradov, Banu Betul Kocaman, Mustafa Sait Gönen, Taner Damci

    Objective: Daily step count is widely accepted as a valuable indicator of physical activity level. The study aimed to test whether it was possible to establish and/or increase patients' connectedness with the pedometer data in their smartphones and smartwatches through a short reminder. Methods: The study included 70 patients whose daily average step count was checked, who provided good glycemic control and whose treatment would not be changed (HbA1c < 7.5%). Demographic and laboratory data of the patients, average step counts in the last 6 months, and smartphone models were recorded, and these data were compared with the data after 6 months. Results: The study included 70 diabetic patients, 30 women and 40 men. The mean number of steps increased from 5587.8 plus/minus 2959 at baseline to 6219 plus/minus 3001 after 6 months. The number of steps increased from 4692 plus/minus 2402 to 6502 plus/minus 2813 in 47 (62%) patients with brief reminder (P < .001). There is a correlation between the increase in the number of steps and the decrease in HbA1c (P < .05). Conclusion: This study demonstrates that a short reminder recited by physicians during the diabetes outpatient clinics visits aimed at increasing connectedness to smartphone/watch daily step count data leads to an increase in daily step count in most of the patients over 6 months. The increase in the daily step count correlated significantly with a decrease in HbA1c levels.